SCHEMBL23791849

SCHEMBL23791849

COc1ccc(-c2nc(Nc3ncc(-c4cccs4)cc3C(=O)O)sc2C(C)C)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FTO Q9C0B1 1/20 0.40
▸ NEK2 P51955 1/20 0.39
▸ PDGFRB P09619 1/20 0.38
▸ PDGFRA P16234 1/20 0.38
▸ KDM4E B2RXH2 6/20 0.38
▸ MEN1 O00255 5/20 0.38
▸ KMT2A Q03164 5/20 0.38
▸ ALDH1A1 P00352 5/20 0.38
▸ RAB9A P51151 4/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ KMO O15229 2/20 0.36
▸ MAPT P10636 7/20 0.36
▸ GAA P10253 3/20 0.36
▸ PIK3CG P48736 2/20 0.36
▸ GSK3B P49841 2/20 0.36
▸ CAMKK2 Q96RR4 2/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ MAPK8 P45983 1/20 0.36
▸ SMN1; SMN2 Q16637 4/20 0.36
▸ HPGD P15428 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23791999 0.91 FTO (0.41) FTOKDM4EMEN1KMT2AALDH1A1
SCHEMBL26479165 0.87 FTO (0.40) FTONEK2PDGFRBPDGFRAKDM4E
SCHEMBL23792008 0.85 DHODH (0.39) FTONEK2MEN1KMT2ARXFP1
SCHEMBL26479171 0.85 FTO (0.41) FTONEK2PDGFRBPDGFRAKDM4E
SCHEMBL25545077 0.84 TNFRSF1A (0.38) NEK2KDM4EMEN1KMT2AALDH1A1
SCHEMBL25545830 0.83 MAPT (0.38) NEK2KDM4EMEN1KMT2AALDH1A1
SCHEMBL23791855 0.83 SORT1 (0.40) KDM4EMEN1KMT2AALDH1A1KMO
SCHEMBL25545222 0.82 ALDH1A1 (0.40) FTONEK2PDGFRBPDGFRAKDM4E
SCHEMBL23792002 0.82 RAB9A (0.41) FTONEK2KDM4EMEN1KMT2A
SCHEMBL23791851 0.81 FTO (0.36) FTONEK2KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 — — US disclosed
WO-2021178488-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. (US) 2021-09-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 FTO 1203/4885NEK2 851/4885PDGFRB 3505/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 FTO 1203/4885NEK2 851/4885PDGFRB 3505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback